Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-04-02 Sale |
2025-04-04 7:27 pm |
Monopar Therapeutics | MNPR | Tactic Pharma LLC Robinson Chandler Brown Michael J O'Halloran Thomas V. Mazar Andrew Paul 10% Owner |
33,334 | $35 | $1,166,690 | 822,255 (Direct) |
View |
| 2021-02-11 Sale |
2021-02-16 7:35 pm |
Monopar Therapeutics | MNPR | Tactic Pharma LLC Mazar Andrew Paul Robinson Chandler O'Halloran Thomas V. Brown Michael J 10% Owner |
125,000 | $14.64 | $1,830,620 | 4,277,940 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-04-01 Option Award |
2025-04-02 1:43 pm |
N/A 2035-03-31 |
ACTUATE THERAPEUTICS INC. | ACTU | Mazar Andrew Paul Chief Operating Officer |
161,392 | $0 | 161,392 (Direct) |
View |
Ownership |
2024-08-12 9:47 pm |
N/A N/A |
ACTUATE THERAPEUTICS INC. | ACTU | Mazar Andrew Paul Chief Operating Officer |
0 | $0 | 164,624 (Direct) |
View |
| 2022-03-31 Exercise |
2022-04-01 5:28 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
1,606 | $0 | 4,388,857 (Direct) |
View |
| 2022-03-31 Tax Withholding |
2022-04-01 5:28 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
471 | $2.55 | 4,388,857 (Direct) |
View |
| 2022-02-02 Option Award |
2022-02-04 7:38 pm |
N/A 2032-02-01 |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
156,125 | $0 | 179,272 (Direct) |
View |
| 2022-01-01 Exercise |
2022-01-04 2:49 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
1,937 | $0 | 4,302,804 (Direct) |
View |
| 2022-01-01 Tax Withholding |
2022-01-04 2:49 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
671 | $3.21 | 4,302,804 (Direct) |
View |
| 2021-12-31 Exercise |
2022-01-04 2:40 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
1,606 | $0 | 4,316,937 (Direct) |
View |
| 2021-12-31 Tax Withholding |
2022-01-04 2:40 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
556 | $3.21 | 4,316,937 (Direct) |
View |
| 2021-09-30 Exercise |
2021-10-01 7:31 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
1,606 | $0 | 4,317,493 (Direct) |
View |
| 2021-09-30 Tax Withholding |
2021-10-01 7:31 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
471 | $4.87 | 4,317,493 (Direct) |
View |
| 2021-06-30 Exercise |
2021-07-02 5:11 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
3,212 | $0 | 4,317,964 (Direct) |
View |
| 2021-06-30 Tax Withholding |
2021-07-02 5:11 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
942 | $5.89 | 4,317,964 (Direct) |
View |
| 2021-01-26 Option Award |
2021-01-28 6:49 pm |
N/A 2031-01-25 |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
61,774 | $0 | 67,585 (Direct) |
View |
| 2021-01-01 Exercise |
2021-01-05 5:38 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
1,937 | $0 | 4,424,020 (Direct) |
View |
| 2021-01-01 Tax Withholding |
2021-01-05 5:38 pm |
N/A N/A |
Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer |
671 | $6.12 | 4,424,020 (Direct) |
View |